Evolving Systems Sets Date for 2020 Second Quarter Results News Release and Conference Call
ENGLEWOOD, Colo., Aug. 06, 2020 (GLOBE NEWSWIRE) — Evolving Systems, Inc. (NASDAQ: EVOL), a leader in real-time digital engagement solutions […]
Datadog Announces Second Quarter Results
Second quarter revenue grew 68% year-over-year to $140 millionStrong growth of larger customers, with 1,015 $100k+ ARR customers, up from […]
Applied Optoelectronics Reports Second Quarter 2020 Results
SUGAR LAND, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access […]
One Stop Systems Reports Q2 2020 Revenue of $11.6 Million with First Half 2020 of $25.0 Million
ESCONDIDO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a global leader in specialized high-performance […]
IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update
– IND for IGM-8444 for treatment of patients with solid cancers cleared by FDA –– Kathy Miller, Ph.D., appointed Vice […]
Merus Announces Financial Results for the Second Quarter and Provides Business Update
– Lead program Zenocutuzumab remains on track –– Dr. Andrew Joe appointed Chief Medical Officer –– Merus extends cash runway […]
First Solar Signs Definitive Agreement to Sell North American O&M Business to NovaSource
TEMPE, Ariz., Aug. 06, 2020 (GLOBE NEWSWIRE) — First Solar, Inc. (Nasdaq: FSLR) today announced that it has entered into […]
Penn Virginia Reports Second Quarter 2020 Results
HOUSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) — Penn Virginia Corporation (“Penn Virginia” or the “Company”) (NASDAQ:PVAC) today announced its financial […]
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company […]
Editas Medicine Announces Second Quarter 2020 Results and Update
Regained full control of ocular medicines under new agreement with AbbVieBRILLIANCE trial for EDIT-101 on track to dose at least […]
